Also a good read..from the International Journal of Cancer Research & Therapy.
Of particular note see page 4, Table 2: Response rates for newer acute myelogenous leukemia therapies in development (bisantrene competitors).
That is, the reported response rates for bisantrene in AML (averaging 48% across historical phase 2 trials) are comparable to the best (46% complete response with Clofarabine), or better than, the majority of drugs (24%-34%) currently in development (Table 2).
Ann: June 2018 Quarterly Report, page-5
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |